Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation

Cancer Science

Volumn 99, Issue 11, 2008, Pages 2120-2127

  Mao, Jianshan ^a   Xu, Zefeng ^a   Fang, Yongming ^a   Wang, Haijun ^a   Xu, Jinghong ^a   Ye, Jinjia ^a   Zheng, Shu ^a   Zhu, Yongliang ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOMA DERIVED GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B;

ADULT; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; FEMALE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH CARCINOGENESIS; STOMACH EPITHELIUM; STOMACH MUCOSA; TUMOR DIFFERENTIATION; TUMOR PROMOTION;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; GASTRIC MUCOSA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; STOMACH NEOPLASMS; TRANSFECTION;

EID: 55449087226     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00928.x     Document Type: Article

References (34)

1. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: A review. Gastric Cancer 2005; 8: 86-94.
2. Yamamoto S, Tomita Y, Hoshida Y et al. Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 2006; 12: 117-22.
3. Nakamura H, Kambe H, Egawa T et al. Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta 1989; 183: 273-84.
4. Nakamura H, Izumoto Y, Kambe H et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor: Its homology with high mobility group-1 protein. J Biol Chem 1994; 269: 25.143-9.
5. Kishima Y, Yoshida K, Enomoto H et al. Antisense oligonucleotides of hepatoma-derived growth factor (HDGF) suppress the proliferation of hepatoma cells. Hepatogastroenterology 2002; 49: 1639-44.
6. Everett AD, Lobe DR, Matsumura ME, Nakamura H, McNamara CA. Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 2000; 105: 567-75.
7. Cilley RE, Zgleszewski SE, Chinoy MR. Fetal lung development: Airway pressure enhances the expression of developmental genes. Pediatr Surg 2000; 35: 113-9.
8. Oliver JA, Al-Awqati Q. An endothelial growth factor involved in rat renal development. J Clin Invest 1998; 102: 1208-19.
9. Everett AD, Narron JV, Stoops T, Nakamura H, Tucker A. Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol 2004; 286: L1194-201.
10. Enomoto H, Yoshida K, Kishima Y et al. Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology 2002; 36: 1519-27.
11. Narron JV, Stoops TD, Barringhaus K, Matsumura M, Everett AD. Hepatoma-derived growth factor is expressed after vascular injury in the rat and stimulates smooth muscle cell migration. Pediatr Res 2006; 59: 778-83.
12. Zhou Z, Yamamoto Y, Sugai F et al. Hepatoma-derived growth factor is a neurotrophic factor harbored in the nucleus. J. Biol. Chem 2004; 279: 27.320-6.
13. Okuda Y, Nakamura H, Yoshida K et al. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci 2003; 94: 1034-41.
14. Yoshida K, Nakamura H, Okuda Y et al. Expression of hepatoma-derived growth factor in hepatocarcinogenesis. J Gastroenterol Hepatol 2003; 18: 1293-301.
15. Hu TH, Huang CC, Liu LF et al. Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer 2003; 98: 1444-56.
16. Yoshida K, Tomita Y, Okuda Y et al. Nakamura. Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 2006; 13: 159-67.
17. Iwasaki T, Nakagawa K, Nakamura H, Takada Y, Matsui K, Kawahara K. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol Rep 2005; 13: 1075-80.
18. Ren H, Tang X, Lee JJ et al. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol 2004; 22: 3230-7.
19. Bernard K, Litman E, Fitzpatrick JL et al. Functional proteomic analysis of melanoma progression. Cancer Res 2003; 63: 6716-25.
20. Uyama H, Tomita Y, Nakamura H et al. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 2006; 12: 6043-8.
21. Matsuyama A, Inoue H, Shibuta K et al. Hepatoma-derived growth factor is associated with reduced sensitivity to irradiation in esophageal cancer. Cancer Res 2001; 61: 5714-7.
22. Abouzied MM, Baader SL, Dietz F, Kappler J, Gieselmann V, Franken S. Expression patterns and different subcellular localization of the growth factors HDGF (hepatoma-derived growth factor) and HRP-3 (HDGF-related protein-3) suggest functions in addition to their mitogenic activity. Biochem J 2004; 378: 169-76.
23. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. Erk (MAPK) activity as a determinant of tumour growth and dormancy; regulation by p38 (SAPK). Cancer Res 2003; 63: 1684-95.
24. Zhu Y, Zhong X, Du Zheng SQ, Xu W. Transformed immortalized gastric epithelial cells by virulence factor CagA of Helicobacter pylori through Erk mitogen-activated protein kinase pathway. Oncogene 2005; 24: 3886-95.
25. Zha J, Harada H, Osipov K, Jockel J, Waksman G, Korsmeyer SJ. BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J Biol Chem 1997; 272: 24.101-4.
26. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-91.
27. Zhu Y, Wang C, Huang J et al. The Helicobacter pylori virulence factor CagA promotes Erk1/2-mediated Bad phosphorylation in lymphocytes: A mechanism of CagA-inhibited lymphocyte apoptosis. Cellular Microbiol 2007; 9: 952-61.
28. Elenitoba-Johnson KS, Jenson SD, Abbott RT et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci USA 2003; 100: 7259-64.
29. Zhang J, Ren H, Yuan P, Lang W, Zhang L, Mao L. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 2006; 66: 18-23.
30. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004; 15: 177-82.
31. Wang H, MacNaughton WK. Overexpressed beta-catenin blocks nitric oxide-induced apoptosis in colonic cancer cells. Cancer Res 2005; 65: 8604-7.
32. Dihlmann S, Kloor M, Fallsehr C, von Knebel Doeberitz M. Regulation of AKT1 expression by beta-catenin/Tcf/Lef signaling in colorectal cancer cells. Carcinogenesis 2005; 26: 1503-12.
33. Wu Y, Hooper AT, Zhong Z et al. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 2006; 119: 1519-29.
34. Wang H, Wang H, Zhang W, Huang HJ, Liao WS, Fuller GN. Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Laboratory Invest 2004; 84: 941-51.